Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant

Novo Nordisk’s shares continued to trend downward Tuesday after reports surfaced that the FDA had recently flagged manufacturing shortfalls at the Danish drugmaker’s Clayton, North Carolina production plant. The facility produces major drug ingredients like semaglutide, the molecule behind Novo’s wildly popular drugs Wegovy and Ozempic.